HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt; a Phase I Study.
Latest Information Update: 19 Jun 2023
At a glance
- Drugs Midostaurin (Primary) ; Siremadlin (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Acronyms HDMM
- 03 Oct 2022 Status changed from recruiting to discontinued.
- 19 Nov 2020 Status changed from not yet recruiting to recruiting.
- 05 Aug 2020 New trial record